Oncology Corporate Profile
XEME Biopharma is a clinical-stage Company focused on developing therapeutic products under the guidance of the Food and Drug Administration (FDA) in the area of active cancer immunotherapy (vaccines). This area of therapeutic cancer vaccines is expected by many oncology specialists to provide the next breakthrough in the treatment of cancer beyond the current approaches of surgery, radiation, chemotherapy and passive immunotherapy (monoclonal antibodies).
|Brand / Product||Class||Area of Study||Phase||Partnership|
|Oncoquest®||personalized cancer vaccine||Non-Hodgkin's Lymphoma (NHL)||II|
|Oncoquest®||personalized cancer vaccine||Chronic Lymphocytic Leukemia (CLL)||I|
View additional information on product candidates here »
12/16/2013 10:05 am
(Medical News Today) Dec 16, 2013 - The oral mammalian target of rapamycin inhibitor everolimus combined with the steroidal aromatase inhibitor exemestane significantly improves the overall response rate in postmenopausal women with advanced breast cancer, according to data released at the SABCS.
3/23/2012 12:31 pm
(ECCO) Mar 23, 2012 - Results from a phase III clinical trial evaluating a new treatment for breast cancer in post-menopausal women show that the combination of two cancer drugs, everolimus and exemestane, significantly improves bone strength and reduces the chances of cancer spreading (metastasising) in the bone.
12/9/2010 12:00 am
(AACR) Dec 9, 2010 - Exemestane, an aromatase inhibitor that blocks production of estrogen, may provide another post-surgery option for postmenopausal women with hormone-receptor positive, early-stage breast cancer.
7/22/2010 12:00 am
(Forbes) July 22, 2010 - Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today that the first patient has received an initial dose in a Phase 2 randomized double blind clinical study combining MM-121 with exemestane (Aromasin®) in breast cancer patients.
12/10/2009 12:00 am
(Yahoo! Finance) Dec 10, 2009 - Pfizer today announced results from an exploratory analysis of the Intergroup Exemestane Study (IES) at a median follow-up of 91 months in estrogen-receptor positive (ER+) or estrogen-receptor unknown (ER-unknown) women that looked at breast cancer free survival (BCFS) and censored deaths that occurred prior to breast cancer relapse.
12/31/1969 06:00 pm